Trending Articles

  1. GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences The company has agreed to acquire a potential best-in-class trispecific T-cell engager with the aim of developing and commercialising it for multiple myeloma, with Phase I...
  2. Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company Long-term agreement extends manufacturing commitments through 2033 and takes cumulative contract value beyond USD 21.9 billion
  3. OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot OutSee will use Innovate UK and Empirical Ventures funding to develop an agentic AI sub-system designed to accelerate initial validation of drug targets identified by its...
  4. AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming...
  5. Almac Group expands US specialised commercial packaging capabilities Almac Group, the global contract pharmaceutical development and manufacturing organisation, is pleased to announce that it has expanded its US commercial packaging capabilities...

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Finance The company has agreed to acquire a potential best-in-class trispecific T-cell engager with the aim of developing and commercialising it for multiple myeloma, with Phase I...
GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences

GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences

Read more
Finance OutSee will use Innovate UK and Empirical Ventures funding to develop an agentic AI sub-system designed to accelerate initial validation of drug targets identified by its...
OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot

OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot

Read more
Manufacturing Long-term agreement extends manufacturing commitments through 2033 and takes cumulative contract value beyond USD 21.9 billion
Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Read more
Manufacturing The expansion brings the site to ten GMP suites by Q1 2027, increasing concurrent capacity for commercial API production and accelerating early-phase programmes — as well as...
Onyx Scientific invests £1.5m into Sunderland API plant

Onyx Scientific invests £1.5m into Sunderland API plant

Read more
Manufacturing The acquisition strengthens PerkinElmer’s pharmaceutical services offering with SimoTech’s expertise in manufacturing automation, digital manufacturing and GMP IT systems
PerkinElmer acquires SimoTech to expand pharma manufacturing automation

PerkinElmer acquires SimoTech to expand pharma manufacturing automation

Read more
Finance Preliminary results: Revenues of 524 million EUR, adjusted EBITDA of 66 million EUR; stronger second half of the year expected
Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Read more
Finance The agreement gives Novartis options to develop and commercialise multiple subcutaneous products using Alteogen’s ALT-B4 hyaluronidase technology
Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery

Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery

Read more
Finance Eli Lilly is acquiring Merida Biosciences in a deal worth up to $2.875bn to expand its pipeline of precision therapies for autoimmune and allergic diseases
Lilly to acquire Merida Biosciences for up to $2.875bn

Lilly to acquire Merida Biosciences for up to $2.875bn

Read more
Finance The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for...
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

Read more
Finance Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs,...
Prescient completes integration of Uptake and Dolon under single global brand

Prescient completes integration of Uptake and Dolon under single global brand

Read more
Packaging Faller Packaging has acquired pharmaceutical packaging specialist Paperpack, expanding its European network and strengthening its presence in South-Eastern Europe
Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging acquires Greek pharma packaging firm Paperpack

Read more
Finance The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming...
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

Read more
Manufacturing The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the...
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

Read more
Research & Development COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

Read more
Finance The Series C financing will support clinical development of Ratio’s Ac-225 radiotherapeutic pipeline and expansion of its radiopharmaceutical manufacturing infrastructure
Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

Read more
Finance A potential AstraZeneca acquisition of Bristol Myers Squibb would create a near-$400bn pharma giant, combining major oncology portfolios and extensive US manufacturing operations
AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

Read more